Clinical Trials Browser

Phase EARLY_PHASE1 × Recruiting × pembrolizumab × Clear all

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell

NCT04265872 2026-02-12

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms

NCT05493566 2026-02-12

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Phase EARLY_PHASE1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05041153 2026-01-12

Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Advanced Gastric Adenocarcinoma

NCT06637306 2025-03-26

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06366451 2025-01-20

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Phase EARLY_PHASE1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04541108 2024-04-18

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Phase EARLY_PHASE1 Recruiting

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma